ArticleBMC biotechnology2026
Construction and application of an insertional activation cloning vector.
Article in BMC biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundForeign DNA cloning is a critical step in genetic engineering and molecular biology for acquiring target genes. Efficient and accurate identification of positive clones from transformants is essential to this process.
resultsHere, we engineered an insertion-activated cloning vector that accepts PCR products directly. In this study, we verified that 60-bp NptII promoters can effectively drive the expression of the mScarlet-I gene. In contrast, the 45-bp NptII promoter can’t drive the expression of the mScarlet-I gene. The insertion-activated cloning vector harbored with the 45-bp truncated NptII promoter and ORF of mScarlet-I gene. This cloning vector contains an EcoRⅤ restriction site, which serves as the cloning site for PCR products. When amplifying exogenous DNA, the designed reverse primer is added with the 15-bp core sequence from − 60 to -46 of the NptII promoter. If the PCR product is cloned into the insertion-activated cloning vector with the correct orientation, the 15-bp core promoter and the 45-bp truncated NptII promoter can be connected and drives expression of the reporter gene, mScarlet-I, which allows positive recombinants to be identified with red fluorescence. Five PCR products with different sizes were tested using the one-step restriction enzyme digestion and ligation approach or in vivo cloning method. The.
conclusionsThe positive selection marker in this insertion-activated cloning vector can achieve higher screening efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.